Physician profile
Katarzyna J Gilek-Seibert
NPI 1972651677
$131,305.74
in general payments reported to CMS, 2019-2025
23 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $3,648 · 2021: $7,496 · 2022: $24K · 2023: $17K · 2024: $36K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $8,527 · Food and Beverage: $7,964 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,375.00 |
| Travel and Lodging | $8,527.29 |
| Food and Beverage | $7,964.08 |
| Education | $369.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120,057.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $5,361.30 | 2019-2025 | Benlysta, Nucala |
| Amgen INC. | $1,224.13 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $926.02 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $825.92 | 2019-2025 | |
| Janssen Biotech, INC. | $760.71 | 2019-2025 | Tremfya |
| Pfizer INC. | $451.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $268.56 | 2019-2025 | Orencia, Sotyktu |
| Lilly USA, LLC | $242.97 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $239.04 | 2022-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $218.40 | 2019-2025 | Strensiq |
| Genzyme Corporation | $200.45 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $185.68 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.44 | 2023 | Cyltezo |
| Genentech USA, INC. | $53.16 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $45.32 | 2022 | |
| Philips North America LLC | $28.97 | 2022-2023 | |
| Radius Health, INC. | $27.30 | 2024 | Tymlos |
| Jazz Pharmaceuticals INC. | $24.69 | 2025 | |
| Verona Pharma, INC. | $23.78 | 2025 | Ohtuvayre |
| Scilex Pharmaceuticals INC. | $22.91 | 2024 | |
| Hikma Pharmaceuticals USA | $19.97 | 2019 | |
| Fresenius Kabi USA, LLC | $17.07 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katarzyna Gilek-Seibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.